ArticleNPJ digital medicine2025
Integrative molecular-radiopathomic characterization of AIRE-driven immune subtypes in bladder cancer.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The efficacy of immunotherapy in bladder cancer (BCa) is highly influenced by tumor heterogeneity, underscoring the urgent need for mechanistic insights and precise molecular subtyping. Adenosine-to-inosine RNA editing (AIRE), a critical post-transcriptional mechanism driving protein diversity, offers a promising lens for decoding the immune microenvironment in BCa. In this study, we established an integrative framework combining molecular, imaging, and pathological data to identify and validate a novel immune-related BCa subtype. Based on multi-center transcriptomic datasets, we employed NMF, WGCNA, and Lasso algorithms to classify tumors into two distinct immune subtypes characterized by different levels of immune cell infiltration and divergent responses to immunotherapy. Mechanistic validation revealed that ANXA1 and RASAL2 may contribute to immunosuppressive niche formation via the TNF-NFκB-CXCL8 axis, potentially acting as molecular triggers for subtype differentiation. Furthermore, radiomic and histopathological analyses at the imaging and tissue levels supported the molecular findings, providing orthogonal validation of subtype-specific characteristics. Collectively, this study introduces an AIRE-based immune molecular subtype of BCa and systematically characterizes it across multiple dimensions. By achieving a closed-loop from identification to validation and clinical translation, our findings offer a new perspective for patients most likely to benefit from immunotherapy and advancing precision treatment strategies in bladder cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.